PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.

Cancers (Basel) · 2021 · PMC8533943 · PMID 34680321

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a trend towards significanceno p-value reported

No significant differences were found between the two PET radiopharmaceuticals on a per-patient-based analysis; conversely, a trend towards significance in favor of 18 F-FDOPA PET/CT was identified on a per-lesion-based analysis [ 28 ].

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.